Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Capital Expenditures for 2 consecutive years, with $3000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures fell 95.31% to $3000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $55000.0 through Dec 2025, down 73.93% year-over-year, with the annual reading at $55000.0 for FY2025, 73.93% down from the prior year.
  • Capital Expenditures hit $3000.0 in Q3 2025 for Silence Therapeutics, down from $48000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $85000.0 in Q2 2024 to a low of $3000.0 in Q3 2025.